Results 51 to 60 of about 14,295 (215)

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

Molecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau, Daniel Pincher, Clifford Young, Nicholas Chappell, Noor A. Lokman, Parul Mittal, Leigh Donnellan, Martin K. Oehler, Doug A. Brooks, Peter Hoffmann   +9 more
wiley   +1 more source

Plasma Biomarkers for Neocortical Tau Burden

JAMA Neurology
Importance Phosphorylated tau-217 (p-tau217) is now an established plasma biomarker for assessing amyloid-β pathology in individuals at risk of Alzheimer disease. However, its performance in identifying advanced neocortical neurofibrillary tangle burden remains suboptimal.
Di Molfetta, Guglielmo, Brum, Wagner S., Pola, Ilaria, Tan, Kübra, Benedet, Andrea L., Sauer, Mathias, Montoliu-Gaya, Laia, Janelidze, Shorena, Mattsson-Carlgren, Niklas, Rahmouni, Nesrine, Chan, Tevy, Denkinger, Marisa N., Proitsi, Petroula, Zetterberg, Henrik, Hansson, Oskar, Rosa-Neto, Pedro, Ashton, Nicholas J.   +16 more
openaire   +2 more sources

A plasma proteomic signature of mitochondrial dysfunction and its diagnostic potential for Type 2 Diabetes Mellitus

Critical Public Health
The escalating global prevalence of Type 2 Diabetes Mellitus (T2DM) poses a significant public health challenge, necessitating improved strategies for early detection.
Siyao Yang, Qian Li, Weimin Chen, Meiling Chen, Ping Huang   +4 more
doaj   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

Interchangeability of blood‐based biomarkers and PET to identify Alzheimer's disease pathology

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Establishing interchangeability between blood biomarkers and amyloid‐positron emission tomography (PET) could help identify patients who would benefit from novel amyloid‐targeting therapies for Alzheimer's disease. METHODS Adult participants
Jian Wang, Joel B. Braunstein, Robin Wolz, Laura Harper, Tricia Locascio, Holly E. McPherson, Richard Mohs, Michael J. Pontecorvo, Samantha C. Burnham   +8 more
doaj   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

Molecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi, Sang‐Hyeon Yoo, Ki‐Jong Rhee   +2 more
wiley   +1 more source

Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease

PLoS ONE, 2011
Peripheral biomarkers of Alzheimer's disease (AD) reflecting early neuropathological change are critical to the development of treatments for this condition. The most widely used indicator of AD pathology in life at present is neuroimaging evidence of brain atrophy.
Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, MECOCCI, Patrizia, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S, for the AddNeuroMed consortium   +17 more
openaire   +7 more sources

Racial and ethnic differences in plasma p‐tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Consistent predictive performance across racial and ethnic groups is essential to the use of plasma biomarkers as screening tools in preclinical Alzheimer's disease trials.
Doris P. Molina‐Henry, Rema Raman, Andy Liu, Oliver Langford, Joel B. Braunstein, Philip B. Verghese, Venky Venkatesh, Shobha Dhadda, Michael Irrizary, Joshua D. Grill, Keith Johnson, Robert A. Rissman, Paul Aisen, Reisa A. Sperling, AHEAD 3‐45 Study Team   +14 more
doaj   +1 more source

UiO‐66 metal–organic frameworks in biomedicine: From structural tunability to bioimaging, photodiagnostics, and photodynamic cancer therapy

FEBS Open Bio, EarlyView.
UiO‐66(Zr) metal–organic frameworks are chemically stable, biocompatible, and highly tunable nanomaterials. Their modular structure enables controlled drug delivery, multimodal bioimaging, and light‐activated photodynamic therapy, supporting integrated diagnostic and therapeutic (theranostic) applications in cancer and biomedical research.
Veronika Huntošová, Grigorii Rakhalskii, Miroslav Almáši   +2 more
wiley   +1 more source

Plasma apolipoprotein A1 as a biomarker for Parkinson disease [PDF]

Annals of Neurology, 2013
Objective To identify plasma‐based biomarkers for Parkinson disease (PD) risk. Methods In a discovery cohort of 152 PD patients, plasma levels of 96 proteins were measured by multiplex immunoassay; proteins associated with age at PD ...
Judy K, Qiang, Yvette C, Wong, Andrew, Siderowf, Howard I, Hurtig, Sharon X, Xie, Virginia M-Y, Lee, John Q, Trojanowski, Dora, Yearout, James, B Leverenz, Thomas J, Montine, Matt, Stern, Susan, Mendick, Danna, Jennings, Cyrus, Zabetian, Ken, Marek, Alice S, Chen-Plotkin   +15 more
openaire   +2 more sources